Acquires former joint ventures in Zimbabwe, Zambia and Mozambique; gains controlling stakes in Kenya and Tanzania; transactions due early 2027; combined operations employ ~170 and generate ~€50m sales.
LATA shows superiority in adolescents; OPERA real‑world suppression comparable to oral regimens; cabotegravir injections rated better than lenacapavir; EXTEND 4M tests 4‑month formulation.
Deal backs new plants, expansions and upgrades across Africa to raise capacity toward an 80 MTPA 2030 target, secure gas supply, improve efficiency, cut emissions and create jobs.
